Literature DB >> 21803632

Genetics of Dupuytren's disease.

Laëtitia Michou1, Jean-Luc Lermusiaux, Jean-Pierre Teyssedou, Thomas Bardin, Johann Beaudreuil, Elisabeth Petit-Teixeira.   

Abstract

Dupuytren's disease (DD) is a progressive fibrosis of the palmar fascia characterized by the formation of a nodule, which evolves into a cord. DD is the most common hereditary disease of the connective tissue preferentially affecting Caucasoids originating from Northern Europe. Some environmental factors are associated with DD, namely alcohol consumption, tobacco exposure and, possibly, manual activities. Diabetes and epilepsy are the most frequently reported DD-associated diseases. The genetic mode of inheritance is not well understood, but seems to be heterogeneous: most frequently, autosomal dominant with variable penetrance, and rarely recessive autosomal or maternal (matrilinear), suggesting a mitochondrial heredity. Initially, a suggestion of linkage with the DUPC1 locus at 16q was proposed. Then, among the genomic variations observed in DD, alterations in the copy number of genes in chromosomal regions 10q22, 16p12.1 and 17p12, associations with the HLA-DRB1*15 allele and a mutation in the rRNA 16s identified in forms with a matrilinear heredity, were reported. Finally, a genome-wide study has shown a genetic association of DD with 6, 11 and 16 chromosomes. Pathophysiology of DD involves mainly myofibroblasts and the extracellular matrix of collagen. Gene and protein expression studies have confirmed the central role of the β catenin of the TGFβ pathways in the pathogenesis of DD.
Copyright © 2011 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803632     DOI: 10.1016/j.jbspin.2011.05.027

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  14 in total

1.  Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.

Authors:  Latha Satish; David B O'Gorman; Sandra Johnson; Christina Raykha; Bing Siang Gan; James H-C Wang; Sandeep Kathju
Journal:  Cell Stress Chaperones       Date:  2013-01-06       Impact factor: 3.667

2.  SNPs previously associated with Dupuytren's disease replicated in a North American cohort.

Authors:  Eric R Anderson; Zhan Ye; Michael D Caldwell; James K Burmester
Journal:  Clin Med Res       Date:  2014-02-26

Review 3.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

4.  Evaluation of a mitochondrial DNA mutation in maternally inherited and sporadic cases of Dupuytren disease.

Authors:  Eric R Anderson; James K Burmester; Michael D Caldwell
Journal:  Clin Med Res       Date:  2012-05-25

5.  Psychometric properties of health-related quality of life instruments in patients undergoing palmar fasciectomy for dupuytren's disease: a prospective study.

Authors:  Achilleas Thoma; Manraj Nirmal Kaur; Teegan Aili Ignacy; Carolyn Levis; Stuart Martin; Eric Duku; Ted Haines
Journal:  Hand (N Y)       Date:  2014-06

6.  Dupuytren's Contracture Cosegregation with Limb-Girdle Muscle Dystrophy.

Authors:  Baiba Lace; Inna Inashkina; Ieva Micule; Inta Vasiljeva; Maruta Solvita Naudina; Jurgis Strautmanis; Janis Stavusis; Eriks Jankevics
Journal:  Case Rep Neurol Med       Date:  2013-08-19

7.  Epidemiological profile of Dupuytren's disease in Taiwan (Ethnic Chinese): a nationwide population-based study.

Authors:  Chin-Choon Yeh; Kuo-Feng Huang; Chung-Han Ho; Kuan-Ting Chen; Cheng Liu; Jhi-Joung Wang; Chin-Chen Chu
Journal:  BMC Musculoskelet Disord       Date:  2015-02-10       Impact factor: 2.362

8.  Identification of histological patterns in clinically affected and unaffected palm regions in dupuytren's disease.

Authors:  Camilo-Andrés Alfonso-Rodríguez; Ingrid Garzón; Juan Garrido-Gómez; Ana-Celeste-Ximenes Oliveira; Miguel-Ángel Martín-Piedra; Giuseppe Scionti; Víctor Carriel; Pedro Hernández-Cortés; Antonio Campos; Miguel Alaminos
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

9.  Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts.

Authors:  Chaoming Zhou; Fang Liu; Phillip H Gallo; Mark E Baratz; Sandeep Kathju; Latha Satish
Journal:  BMC Musculoskelet Disord       Date:  2016-11-11       Impact factor: 2.362

10.  Dupuytren's Contracture in Alabama HFE Hemochromatosis Probands.

Authors:  James C Barton; J Clayborn Barton
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2012-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.